• There is no registration fee, but registration is mandatory regardless of whether or not an abstract is submitted.
• Attendees may register HERE
• All trainees are encouraged to attend whether they have a presentation or not.

January 7: Final submission of abstracts

January 21: Committee Abstract review process will conclude

January 22: Conference call with reviewers

February 1: Final call with reviewers

February 9: Acceptance letters sent out

March 8: Dinner at Harvard Club

DEADLINE TO SUBMIT ABSTRACTS IS NOW CLOSED.
THANK YOU FOR ALL WHO SUBMITTED

All abstracts submitted must be understandable to a diverse audience including clinical and non-clinical faculty.

Director, Rutgers Cancer Institute of New Jersey
Vice Chancellor for Cancer Program, Rutgers Biomedical and Health Sciences, Rutgers The State University of New Jersey
Senior Vice President, Oncology Services, RWJBarnabas Health
Professor, Department of Surgery, Rutgers Robert Wood Johnson Medical School
Affiliated Distinguished Professor in Genetics, SAS Department of Genetics

Steven K. Libutti, MD, FACS was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is a Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents.

Brigham and Women’s Hospital

Gerard M. Doherty, MD

Moseley Professor of Surgery, HMS